Zenotech Laboratories Q4FY26 Results: Net loss ₹107 lakh, revenue up 1.5%
- Zenotech Laboratories posted a net loss of ₹107.21 lakh in FY26 versus a profit of ₹561.29 lakh in FY25
- Revenue grew 1.5% YoY to ₹3,956.20 lakh, driven by a 15% increase in volumes
- Shareholders approved material related party transactions with Sun Pharmaceutical Industries Limited
- Prior period tax expenses of ₹48.93 lakh were adjusted against FY26 earnings
*this image is generated using AI for illustrative purposes only.
Zenotech Laboratories Limited swung to a net loss of ₹107.21 lakh in FY26, compared to a profit of ₹561.29 lakh in the previous year. The company attributed the bottom-line deterioration to prior period tax expenses of ₹48.93 lakh adjusted against current year earnings.
Revenue from operations grew marginally by 1.5% to ₹3,956.20 lakh in FY26, up from ₹3,897.57 lakh in FY25. The top-line growth was supported by a 15% increase in volumes, primarily driven by the Oral Solid Dosage (OSD) and Ophthalmic sectors.
Key Financial Metrics
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹3,956.20 lakh | ₹3,897.57 lakh | +1.5% |
| Profit/Loss After Tax | -₹107.21 lakh | ₹561.29 lakh | Swing to Loss |
| Prior Period Tax Expense | ₹48.93 lakh | N/A | N/A |
AGM Approvals and Governance
The company’s 37th Annual General Meeting (AGM), held via video conferencing on September 25, 2026, approved several key resolutions. Shareholders adopted the audited standalone financial statements for FY26 and re-appointed Mr. Jignesh Anantray Goradia as Director, who retired by rotation.
A significant approval was granted for material related party transactions with Sun Pharmaceutical Industries Limited, the promoter and holding company of Zenotech Laboratories. The Chairman noted that the company continues to work closely with Sun Pharma to share best practices and establish new standard operating procedures.
What the Numbers Show
The divergence between volume growth and profitability highlights operational pressure. While volumes increased by 15%, revenue growth was limited to 1.5%, suggesting significant pricing pressure or a shift in product mix toward lower-value items within the OSD and Ophthalmic segments. The swing to a net loss was not solely due to operational performance but was heavily impacted by the ₹48.93 lakh prior period tax adjustment, which accounted for nearly half of the reported loss magnitude.
Historical Stock Returns for Zenotech Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.13% | -6.33% | -7.36% | +15.29% | -20.34% | -14.68% |
How will Zenotech address the significant gap between 15% volume growth and only 1.5% revenue growth to restore pricing power in FY27?
What specific operational efficiencies is Sun Pharma implementing through the approved related party transactions to help Zenotech return to profitability?
Are there plans for Zenotech to shift its product mix toward higher-margin formulations to counteract the current pricing pressure in OSD and Ophthalmic segments?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
